Pattern Bioscience
Pattern Bioscience is dedicated to revolutionizing bacterial infection diagnosis and combating antibiotic resistance through its innovative single-cell microbiology platform. Founded in 2016 and based in Austin, Texas, the company develops rapid, culture-free diagnostic technologies that provide actionable results within hours, significantly reducing the time for pathogen identification and antibiotic susceptibility testing. Its mission is to improve patient outcomes, reduce healthcare costs, and address the global crisis of antimicrobial resistance by enabling faster, smarter diagnostics.
Industries
Nr. of Employees
medium (51-250)
Pattern Bioscience
9600 Great Hills Trail, Suite 160E, Austin, TX 78759
Patents
Apparatuses for contactless loading and imaging of microfluidic chips and related methods
US-12128415-B2
View DetailsCompositions and methods for identifying, quantifying, and/or characterizing an analyte
US-11268135-B2
View Details
Apparatuses for contactless loading and imaging of microfluidic chips and related methods
US-12128415-B2
View DetailsCompositions and methods for identifying, quantifying, and/or characterizing an analyte
US-11268135-B2
View DetailsProducts
Single-cell microbiology diagnostic platform (in development)
A culture-free diagnostic system that isolates and measures individual bacterial cells to generate identification and phenotypic antibiotic susceptibility data in hours.
Pneumonia ID/AST panel (in development)
A direct-from-specimen phenotypic identification and susceptibility panel designed to provide same-day actionable results for hospitalized patients with pneumonia.
Bacteremia ID/AST panel (in development)
An ID/AST panel intended to identify bloodstream pathogens and provide phenotypic susceptibility results directly from positive blood-culture samples without additional culturing steps.
Single-cell microbiology diagnostic platform (in development)
A culture-free diagnostic system that isolates and measures individual bacterial cells to generate identification and phenotypic antibiotic susceptibility data in hours.
Pneumonia ID/AST panel (in development)
A direct-from-specimen phenotypic identification and susceptibility panel designed to provide same-day actionable results for hospitalized patients with pneumonia.
Bacteremia ID/AST panel (in development)
An ID/AST panel intended to identify bloodstream pathogens and provide phenotypic susceptibility results directly from positive blood-culture samples without additional culturing steps.
Services
Design and execution of clinical validation studies and preparation of regulatory submissions to support diagnostic panel clearance, including engagement with regulatory programs that enable interactive communication during development.
Design and execution of clinical validation studies and preparation of regulatory submissions to support diagnostic panel clearance, including engagement with regulatory programs that enable interactive communication during development.
Expertise Areas
- Clinical microbiology diagnostics
- Rapid phenotypic ID/AST development
- Single-cell analysis and microfluidics
- Machine learning for diagnostic pattern recognition
Key Technologies
- Single-cell analysis
- Droplet microfluidics
- Phenotypic antimicrobial susceptibility testing
- Machine learning / deep learning
News & Updates
Founder and former CEO Nick Arab to transition to CTO and focus on advancing Pattern's single-cell microbiology technology.
Pattern Bioscience has been awarded a cost-share contract worth up to $40.9 million by BARDA to develop its rapid diagnostic platform for bacterial infections, focusing on pneumonia and bacteremia.
Pattern Bioscience was named the winner of the Disruptive Technology Award from the Association for Diagnostics & Laboratory Medicine for its innovative rapid diagnostic platform based on single-cell microbiology.
Pattern Bioscience announced a Series C funding round to accelerate development of its rapid infectious disease diagnostic platform, with a focus on pneumonia and bacteremia.
Carey-Ann Burnham, a renowned microbiologist, was appointed as Chief Clinical Officer to oversee clinical and regulatory strategy for Pattern's rapid pathogen identification and antibiotic susceptibility testing platform.
Pattern Bioscience announced that Carey-Ann Burnham, PhD, has been appointed as the company's new CEO, with founder Nick Arab transitioning to CTO.
Founder and former CEO Nick Arab to transition to CTO and focus on advancing Pattern's single-cell microbiology technology.
Pattern Bioscience has been awarded a cost-share contract worth up to $40.9 million by BARDA to develop its rapid diagnostic platform for bacterial infections, focusing on pneumonia and bacteremia.
Pattern Bioscience was named the winner of the Disruptive Technology Award from the Association for Diagnostics & Laboratory Medicine for its innovative rapid diagnostic platform based on single-cell microbiology.
Pattern Bioscience announced a Series C funding round to accelerate development of its rapid infectious disease diagnostic platform, with a focus on pneumonia and bacteremia.
Carey-Ann Burnham, a renowned microbiologist, was appointed as Chief Clinical Officer to oversee clinical and regulatory strategy for Pattern's rapid pathogen identification and antibiotic susceptibility testing platform.
Pattern Bioscience announced that Carey-Ann Burnham, PhD, has been appointed as the company's new CEO, with founder Nick Arab transitioning to CTO.